Saturday, July 22, 2006
Volume 7, Issue 7

In This Issue:

1) Current Market Metrics - Mutual Fund Flows
2) Recent Blog Research Features
3) Viewing the Market
    A) Don't get too bearish
    B) Is the Economy Running Out of Steam?
4) Feature Stock #1 - Yahoo! (YHOO)
5) Feature Stock #2 - Forest Laboratories, Inc. (FRX)
6) Additional Stocks - Worth a Further Look
    A) Morgan Stanley (MS)
    B) OMI Corporation (OMM)
7) About VitalStocks.com
8) DISCLAIMER:  Use of this newsletter signifies your acceptance of this disclaimer.

 RSS Feed available: Fresh content each weekday http://feeds.feedburner.com/VitalstocksInvestingNewsletterDigest

This issue sponsored by...
==============================================

==============================================

1) Current Market Metrics:

- NEW YORK, July 20 (Reuters) - Investors pulled a net $5.25 billion from equity funds in the week ended July 19, exceeding the prior week's outflows of $920 million, TrimTabs Investment Research estimated on Thursday.
Full Article

---------------------------------------------------------------------

Independent Data on Fund Flows
Data As Of: 19 July 2006

- Including ETF activity, Equity funds report net cash outflows totaling -$5.839 billion in the week ended 7/19/06 with Domestic funds reporting net outflows of -$4.999 billion and Non-domestic funds reporting net outflows totaling -$840 million;

- Money Market funds report net cash inflows of $6.581 billion;

Source (Much more information available): http://www.amgdata.com/

>>> Back to Table of Contents <<<

==============================================

Please support us - visit our blog and share an article with a friend.

2) Recent Research Articles - Actionable investment research and commentary, unedited, straight from the pros.  (Click to read a post)

2A) (PHRM) - exceeded earnings estimates in eight out of the past nine quarters, with each of the positive surprises exceeding 20%:

http://www.vitalstocks.com/blog/2006/07/phrm-exceeded-earnings-estimates-in.html

2B) (CMTL) - strong history of topping analysts' estimates, having done so for an amazing 13 quarters in a row:

http://www.vitalstocks.com/blog/2006/07/cmtl-strong-history-of-topping.html

2C) (EYE) - Advanced Medical Optics has risen about 35% since May 31, 2005 and set new highs on Tuesday:

http://www.vitalstocks.com/blog/2006/07/eye-advanced-medical-optics-has-risen.html

2D) (MTLM) - company surprised to the upside by an impressive 28.4%:

http://www.vitalstocks.com/blog/2006/07/mtlm-company-surprised-to-upside-by.html

==============================================

3) Viewing the Market:  Financial analysts / journalists comment on the current stock market and future direction.

3A) Don't get too bearish

It is easy right now to abandon the notion that the bulls have any chance at holding the long-term primary trend line. Despite several bad days, the long-term primary trend was tested hard. The risk of the war spreading into Syria and Iran and involving the whole Middle East is extremely threatening and yet the long-term primary trend held.

Before you go and short the stock market up to your eye balls and prepare for Armageddon, let's look at what the bulls may be thinking and pondering. I have argued for months that the Fed has maintained a pattern of expanding one quarter and then contracting the next. The Fed has maintained this quarterly pattern since 2003. Based on this pattern we should expect to see the money supply, or liquidity, start to grow. And that is exactly what we are starting to see.

We need to be careful to not get too bearish here if we start to see a zooming rate of change in the money supply. An expanding money supply is what expands the economy. I remember one of the biggest surges in the money supply occurred just before our military attack Iraq in 2003.

Short cycles are now deeply oversold, suggesting a bounce could take place any time now. Fear is approaching extremes again - often a prelude to a rally advance. Let's see if the market continues to hold here or not.

Stocks that Could Double in a Year

Smith & Wesson Holding Corporation (SWB) is the largest manufacturer of handguns in the United States and the largest U.S. exporter of handguns. The Company manufactures revolvers, pistols, and related products and accessories for sale primarily to gun enthusiasts, collectors, hunters, sportsmen, protection focused individuals, public safety agencies and officers, and military agencies in the United States and throughout the world.

Meadowbrook Insurance Group (MIG) is a holding company organized as a Michigan corporation in 1985. The Company was formerly known as Star Holding Company and in November 1995, upon acquisition of Meadowbrook, Inc. (“Meadowbrook”), they changed their name. Meadowbrook was founded in 1955 as Meadowbrook Insurance Agency and was subsequently incorporated in Michigan in 1965.

On the Stealth Stocks Watch List

TETRA Technologies, Inc. (TTI) operates as an oil and gas services company worldwide. It manufactures integrated calcium chloride and brominated products, and supplies feedstocks to energy and other markets.

Interstate Hotels & Resorts, Inc. (IHR) operates as a hotel management company in the United States. It operates in three segments: Hotel Management, Hotel Ownership, and Corporate Housing. The Hotel Management segment manages hotels under various brand names, including Marriott, Hilton, Sheraton, Westin, Radisson, Doubletree, Embassy Suites, Wyndham, and Holiday Inn

Chaparral Steel Company (CHAP) produces structural steel and steel bar products in North America. Its structural steel products include wide flange beams, channels, piling products, and other shapes.

Courtesy: http://www.stealthstocksonline.com

>>> Back to Table of Contents <<<

==============================================

What do we pick?

VitalStocks newsletter presents the two best ideas from the commentary of the week.  Here is the secret:  We take all those ideas and compare each stock to various industry averages.

Professionals pay thousands of dollars per year for access to this information.  Our publishers feel some investors need to take a test drive before purchasing the investing newsletters of their choice.

Submit all comments or ideas: webmaster@vitalstocks.com

==============================================

3B) Is the Economy Running Out of Steam?

Kelley Wright, editor of the Investment Quality Trends newsletter, doesn’t believe the geopolitical problems are having the biggest impact on the market. Instead, it may be that the market is finally becoming aware of the bearish trends it has been trying to ignore. In this featured expert, Wright offers his investment outlook and a pair of stock profiles.

Investment Outlook from July 14

Why are the markets really declining, except for oil and gold of course? Kelley Wright’s view is that the Street is starting to acknowledge that the growling noise they have been hearing is coming from the big bear in the living room they have been trying to pretend isn’t there.

Also, despite the conventional wisdom that The Pause is finally here, Wright suspects the Federal Reserve will continue to raise interest rates, and it may continue to do so even after the meeting in August. The fact that the bond market is signaling enough already will fall on deaf ears until something breaks. By all indications that something will be the housing market, unless of course the stock market joins in as well.

In any event debt is becoming more expensive. The question that hangs out there is will there ever be a point at which the consumer capitulates and cries uncle?

What isn’t in doubt is the mounting evidence that the U.S. economy is finally starting to run out of steam. Home Depot (HD), in Wright’s opinion the new proxy for the US economy, has been taken out and shot as can be witnessed by its decline to lows not seen for two years. In question is if this is the housing slump moving to secondary positions such as HD and Masco (MAS), or if shareholders anger over the CEO’s compensation and the underreported fact that HD’s application to create a bank a la Wal-Mart (WMT) has run into seemingly intransigent opposition in Congress.

At the time of this writing it appears that whatever the catalyst HD is poised to offer an even higher dividend yield. While the IQT parameters of Undervalue and Overvalue dividend yields are repetitive over significant time periods, Wright would remind subscribers that these levels are not inviolate. Indeed, both the markets in general and individual stocks can move above and below these repetitive levels during periods of excessive emotion and volatility. As for the Select Blue Chips that occasionally offer a dividend yield that exceeds their historic level of Undervalue, more often than not this proves to be an exceptional buying opportunity when viewed from the luxury of hindsight at some point in the future.

Underlying all of the above is that crude oil doesn’t look like it will be declining below $70 anytime soon. To add insult to injury, Wright’s contacts in the futures markets have shared tales of some very interesting buying taking place in the crude oil pits.

One has to question when and if these factors will take their toll on corporate earnings. The Big Money appears to think the time is now considering how the Street has been reacting to the early earnings announcements. We’ll know more next week when earning’s season kicks into high gear.

In conclusion none of the above is new news; Mr. Market may just be starting to care though. In Wright’s experience, this can make the Fourth of July fireworks look like sparklers.

Courtesy: http://www.zacks.com/experts/featured/view_article.php?art_id=2548&newsletter_id=15

>>> Back to Table of Contents <<<

==============================================

==============================================

4) Feature Stock #1 – Yahoo! (YHOO)

>>> Back to Table of Contents <<<

VitalStocks.com Research Summary:
Data as of: 21 July

Price / Cash Flow Ratio is 49.8% of the Industry Average.

Forward Price to Earnings Growth (PEG): 1.73

Debt / Equity Ratio is 112.5% of the Industry Average.

Net Profit Margin is 107.1% of the Industry Average.

Return on Equity is 108.0% of the Industry Average.

Current P/E Ratio is 66.0% of the Industry Average.

5-Year Avg. Pre-Tax Profit Margin is 813.3% of the Industry Average.

Price/Sales Ratio is 71.0% of the Industry Average.

Income Per Employee is 138.7% of the Industry Average.

MSN Money Price Target:  http://moneycentral.msn.com/investor/research/wizards/srwtarget.asp?Symbol=yhoo

==============================================

>>> Back to Table of Contents <<<

5) Feature Stock #2 – Forest Laboratories, Inc. (FRX)

Outlook

Forest Laboratories, Inc. focuses on the therapeutic areas of the central nervous, cardiovascular and respiratory systems, as well as research and development programs that address a range of health conditions. Principal brands include Lexapro for depression, Namenda for Alzheimer's disease, and Benicar for high blood pressure. Fiscal 2006 was a transition period for Forest with earnings declining due to loss of Celexa sales and higher R&D spending. We remain enthusiastic about the potential for further growth in the Lexapro and Namenda products. Growth should return this year, but until visibility improves we rate the shares hold with a $45 target.

Overview

Forest Laboratories, Inc. (FRX) and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical prescription drug products, as well as non-prescription pharmaceuticals sold over-the-counter. Forest Laboratories has well-established franchises in therapeutic areas of the central nervous, cardiovascular and respiratory systems, as well as research and development (R&D) programs that address a wide range of health conditions. Principal brands include Lexapro (escitalopram oxalate) for depression, Namenda (memantine HCl) for Alzheimer's disease, and Benicar (olmesartan medoxomil) for high blood pressure. Based in New York, Forest Laboratories has operations on Long Island, as well as in New Jersey, Missouri, Ohio, Ireland and the U.K. The company employs 5,050 people worldwide.

Bull Story

Sales of Forest Laboratories anti-depressant drug Lexapro account for over half of the company's top line. In fact, in fiscal 2006 Lexapro accounted for 63% of total revenues. Lexapro is FRX's next generation selective serotonin reuptake inhibitor (SSRI), a molecule that helps restore the brain's chemical balance by increasing the available supply of serotonin, a substance in the brain believed to influence mood. Lexapro is a treatment for both depression and generalized anxiety disorder (GAD) in adults. Currently, more than 19 million American adults suffer from depression and four million American adults suffer from GAD. Forest is also working to expand the Lexapro label into other areas of psychiatric disorder such as social anxiety, panic disorder, obsessive-compulsive disorder and posttraumatic stress disorder. These are all rather large markets. Lexapro offers both excellent efficacy and tolerability relative to the company's first-generation SSRI, Celexa. We have also seen impressive clinical data demonstrating Lexapro's clinical advantages relative to other depression category therapies, such as Zoloft (Pfizer) and Paxil (GlaxoSmithKline). Lexapro may be the best-in-class SSRI as demonstrated by category leading growth and market share. Management discussed plans to have the sales force step up promotion based on the data from some new clinical trials. The category remains highly sensitive to product detailing; this is a positive for Forest Labs considering that we expect Pfizer to cease heavy promotion of Zoloft which lost exclusivity in June 2006. Lexapro sales for fiscal 2006 (ended March 2006) were $1.9 billion in-line with our forecast. Going forward, sales should benefit from an 8% price increase implemented this year. Lexapro sales in the first quarter of fiscal 2007 came in at $507 million, exceeding our expectations by $2 million. For the fiscal year 2007, we expect Lexapro to post sales of approximately $2.1 billion, up 10% from fiscal 2006.

Forest Laboratories also possesses enormous potential with Alzheimer's disease drug Namenda. Alzheimer's disease (AD) impacts roughly 4.5 million Americans. The AD market is rather wide-open, and we view Namenda as a potential breakthrough therapy for this debilitating disease. Namenda is currently approved for moderate-to-severe AD. The FDA surprisingly issued a not approvable letter to Forest Labs for expanding the label to include more mild cases in July 2005. This was a shock to us considering the previous guidelines issued by the FDA on what was necessary to achieve approval. Nevertheless, Forest is discussing the application with the FDA in hopes to eventually gain approval for the expanded population. We see Namenda overtaking Aricept (Pfizer) as the category leader within the next few years; although roughly three-quarter of Namenda use is in combination with acetylcholinesterase inhibitors like Aricept, Razadyne (J&J) and Exelon (Novartis). Improved patient access and increased promotional efforts should help drive growth for the product. For fiscal 2007, we see Namenda posting sales of $626 million, slightly above the company's guidance. We believe the compound memantine (Namenda) could offer near billion-dollar sales potential based on expanding the label to include neuropathic pain (phase II) and post herpetic neuralgia (phase II).

In the first quarter of fiscal 2007, hypertension drug Benicar/HCT, an angiotension II receptor blocker, delivered $41.7 million in income to Forest Labs through the profit-split with distributor Sankyo. Benicar remains a prescription market share gainer and should post 40-45% growth in a category that is only expected to deliver 7-8% growth.

We are also optimistic about a number of late-stage and recently approved products that will contribute to growth in the coming years. Forest launched Campral for the treatment of alcohol dependency (maintenance of alcohol abstinence), in early January 2005. Campral prescriptions were in-line with our thinking for the first few months on the market. Perhaps the biggest wildcard product candidate in Forest's pipeline is milnacipran, a norepinephrine serotonin reuptake inhibitor (NSRI) for the treatment of fibromyalgia syndrome and pain associated with fibromyalgia. Fibromyalgia is a chronic pain illness characterized by musculoskeletal aches, pains, stiffness, soft tissue tenderness and general fatigue. The disease is rather common in the U.S., with approximately 3-6% of the population suffering from either some combination of these symptoms or chronic fatigue syndrome (CFS). Phase III data released in late September failed to demonstrate statistical significance, but the companies plan to continue development of milnacipran further in two additional phase III trials. The company is enrolling patients for these trials and we do not expect to see results from these trials before mid CY2007. If Forest Labs can demonstrate that milnacipran offers a viable therapy against fibromyalgia pain, the drug may have multihundred million dollar potential.

Another late-stage candidate, desmoteplase (a blood-clot dissolving agent) seems under-appreciated by the Street. We believe that Forest's late-stage pipeline should begin to attract significant attention throughout the year. We believe that milnacipran, nebivolol, and desmoteplase will be key long-term drivers of growth at Forest Labs.

The fiscal fourth quarter has been very active for Forest Labs. In January 2006, Forest Labs paid $75 million upfront to Mylan Labs for nebivolol. The drug is a long-acting, cardio-selective beta-blocker with mild vasodilating properties. The unique characteristics of the drug such as its low side-effect profile and the potential to achieve superior efficacy in diabetic or African-American patients could make it a blockbuster. Nebivolol was designated approvable by the FDA for hypertension in June 2005. Forest Labs will be conducting an additional preclinical study and a pharmacokinetic (PK) study, which will form the basis of the company's response to the approvable letter. We believe the company is on track to submit its response by the end of 2006. At that time, the company expects a six-month review period. The company also expects to conduct a large-scale phase IV trial to test the diabetic and African-American hypothesis, as well as a phase III trial in congestive heart failure (CHF). A filing for the CHF indication should also take place in the second half of calendar 2006. We model the product launch in the first half of calendar 2007. Forest will pay royalties to Mylan Labs. In February 2006, the company licensed faropenem medoxomil from privately held Replidyne, Inc. for an upfront payment of $50 million and future royalties and milestones on sales. The drug is an oral broad-spectrum antibiotic with improved bioavailability over older generation faropenem products. The NDA was filed in December 2005 by Replidyne for the treatment of acute bacterial sinusitis, community - acquired pneumonia, acute exacerbation of chronic bronchitis and uncomplicated skin and skin structure infections in adults. The NDA has since been accepted by the FDA and a response should be out by October 20, 2006. On the first quarter conference call, the company indicated that it would need approval for at least two indications for the product to be successful. If the company succeeds in gaining full approval later this year, the product launch should take place in late summer 2007, just before the start of the cough-cold season. However, the product launch could get delayed by a year if the FDA requests the company to submit additional data. Forest is already conducting additional studies. We are currently modeling the product launch in mid 2007. We are positive on both in-licensing deals. Based on our long-term projections, both deals should be accretive in fiscal 2008.

We are pleased to see that Forest is continuing to work on building its pipeline. The company recently added another candidate to its pipeline by entering into a deal with privately held Almirall. LAS34273, a long-acting muscarinic antagonist, is scheduled to enter into phase III trials for chronic obstructive pulmonary disorder (COPD). COPD is the fifth leading cause of death worldwide and the fourth in the U.S. Phase II results showed that the candidate has a fast onset of action and provides 24 hours of bronchodilation. LAS34273 is being developed in a multi dose dry-powder inhaler, which represents an improved form of drug delivery over the currently available devices. Forest will sell and market the product in the U.S.

Bear Story

The overall anti-depression franchise at Forest showed negative growth in fiscal 2006 as its first generation product, Celexa, succumbed to generic competition. The product posted sales in fiscal year 2004 of just over $1 billion. This number fell to $653 million in fiscal year 2005. Multiple generic alternatives were launched in early November 2004. Celexa posted sales of just $19 million in fiscal 2006, in-line with our estimate.

Perhaps the biggest near-term risk to Forest Labs was the company's patent infringement lawsuit with Teva Pharmaceuticals for Lexapro. Lexapro is patent protected through at least September 2011 (March 2012 with pediatric extension), yet there are several (paragraph IV) challenges that seek to bring an alternative product to the market sooner. Forest received a major boost recently when a federal judge ruled in its favor in the patent infringement case with Teva. Teva has the option to appeal the ruling. On the first quarter conference call, Forest announced that it is not yet aware of Teva's future course of action. Teva already has FDA approval for its generic version of the drug. Meanwhile, Forest and H. Lundbeck have filed a patent infringement lawsuit against Caraco Pharmaceuticals which is seeking approval for a generic version of Lexapro. Forest intends to defend the Lexapro patent vigorously.

Generic Celexa, Paxil, and Prozac are creating enormous pricing pressure on branded drugs such as Lexapro. Although we believe Lexapro to be best-in-class , Forest Labs may find it difficult to maintain pricing once generic versions of Zoloft, the category leader, hit the market by the end of July.

Forest has had its share of R&D failures over the past year. Above we discussed the recent failure of a phase III trial on milnacipran in Fibromyalgia. Management recently expanded the second phase III trial
from 800 to 1,200 patients, delaying the data until mid 2007. At this time we do not model any revenue contribution from milnacipran until fiscal 2009.

Earlier in 2005 the company announced that its phase III candidate, neramexane, failed to achieve statistical significance in a safety and efficacy trial studying the drug for Alzheimer's disease. The result from this study was surprising, considering the company had high hopes for this drug. We believed neramexane, an NMDA receptor agonist, offered another large potential in Alzheimer's disease along with Namenda. The company has conducted additional AD studies, one completed in mid July 2005. Forest is planning to study neramexane in other central nervous system (CNS) disorders, and will initiate phase II trials shortly. Meanwhile, the company announced that it will be moving neramexane into an additional phase III trial for AD by the end of this year. We do not model any neramexane contribution in the coming years despite the recent positive proof-of-concept data. We consider visibility on both milnacipran and neramexane to be low. Likewise, Lexapro received a non-approvable letter from the U.S. Food and Drug Administration on March 30, 2005 for social anxiety disorder (SAD). This was a surprise considering the drug is already approved for generalized anxiety disorder (GAD). This rejection follows a non-approvable letter for panic disorder earlier. The company will need to conduct additional clinical trials to expand the Lexapro label to include these indications.

Finally, the recently launched Combunox, a combination ibuprofen and oxycodone, pill looks dead. Management decided to cease marketing and promotion for the drug after a very sluggish first nine months on the market. We had previously thought that the drug would have sales of around $100 million given the high demand for pain medication in a post-Vioxx market. Now we have slashed the product down to insignificant levels. This was an unfortunate failure given the previous management enthusiasm around the drug.

Valuation

Forest Laboratories currently sells for 19.2x our calendar 2006 EPS estimate of $2.22. Fiscal 2006 was a transition period for the company with earnings declining primarily due to the lost sales of Celexa and the $125 million up-front R&D payments to Mylan and Replidyne. While Celexa sales declined from over $1 billion in fiscal 2004 to $19 million in fiscal 2006, R&D expense increased to $410 million, mainly due to two milestone payments in the fourth quarter of FY2006.

We are also disappointed with the recent R&D failures at Forest Labs. Pipeline drugs milnacipran and neramexane both failed to demonstrate statistical significance in phase III trials. Forest will head back to the drawing board with more phase II and phase III trials for both. Couple these failures with the label expansion setbacks to Lexapro and the pulling of marketing efforts for Combunox, and we see investors waiting on the sideline until growth returns in fiscal 2007. Investor attention now turns to the recently acquired nebivolol and faropenem, and phase III candidate desmoteplase. Both deals for nebivolol and faropenem are positive in our view. Both should be accretive in fiscal 2008.

We believe FRX shares may begin to recover eventually in calendar 2006 as investors start looking at the strong return to top-line and earnings growth in fiscal 2007. Yet, we believe investors can be patient while anticipating that recovery. The stock was up 15% recently when a federal judge ruled in favor of Forest in its Lexapro patent infringement case with Teva. The favorable ruling removes a significant overhang on the stock and will allow investors to focus on the company's pipeline prospects. We rate FRX a Hold with a $45 price target. Our target is based on 20.3x our calendar 2006 estimate of $2.22.

Content Courtesy: Zacks Investment Research

>>> Back to Table of Contents <<<

VitalStocks.com Research Summary:
Data as of: 21 July

Price / Cash Flow Ratio is 95.6% of the Industry Average.

Forward Price to Earnings Growth (PEG): 0.66

Debt / Equity Ratio is 0.0% of the Industry Average.

Net Profit Margin is 477.1% of the Industry Average.

Return on Equity is 503.9% of the Industry Average.

Current P/E Ratio is 23.0% of the Industry Average.

5-Year Avg. Pre-Tax Profit Margin is 573.3% of the Industry Average.

Price/Sales Ratio is 158.5% of the Industry Average.

Income Per Employee is 761.1% of the Industry Average.

MSN Money Price Target:  http://moneycentral.msn.com/investor/research/wizards/srwtarget.asp?Symbol=FRX

==============================================

>>> Back to Table of Contents <<<

6) Additional Stocks - Worth a Further Look

6A) Morgan Stanley (MS)

Morgan Stanley (MS), a stock that we first featured on Mar 29, 2006, has continued its winning ways. The company has maintained its Zacks #1 Rank due to its history of topping analysts' expectations while experiencing upward estimate revisions. Earnings per share are projected to grow 12.6% over the next 3-5 years. MS has a current dividend yield of 1.7%.

Full Analysis

Morgan Stanley is a global financial services firm that operates in four segments: institutional securities, retail brokerage, asset management and Discover. With more than 600 offices in 30 countries, the company's diverse client base includes corporations, governments, financial institutions and individuals.

When MS was first highlighted as a Growth and Income stock on Mar 29, 2006, it had topped the consensus earnings estimate for the past three quarters by an average margin of 24.8%. The company continued its winning ways by beating the Street yet again in its most recent quarter, and has now done so in 13 out of the past 15 quarters. Furthermore, and most importantly, it is still a Zacks #1 Rank.

On Jun 21, 2006, MS posted second-quarter fiscal 2006 profits of $1.85 per share, surprising to the upside by a solid 28.5%. Earnings were almost a dollar better than the 86 cents per share achieved in the prior-year period. Net revenues soared 48.3% to a new record of 8.9 billion. Chairman and CEO John J. Mack stated, "I could not be more pleased with the outstanding results the employees of Morgan Stanley delivered in the second quarter. There is still a great deal of work to be done, but we are moving aggressively on many fronts and we see significant opportunities to create shareholder value."

For the first six months of fiscal 2006, profits and net revenues were up 51.0% and 34.9%, respectively, when compared to the first six months of fiscal 2005. Earnings per share are projected to grow 12.6% over the next 3-5 years.

Consensus estimates for this quarter and next jumped 11.4% and 4.2%, respectively, over the past 90 days. Profit forecasts for fiscal 2006 and fiscal 2007 have risen 12.9% and 6.0%, respectively, over the same time period.

On May 31, 2006, the Board of Directors declared a quarterly cash dividend of 27 cents per share of common stock. The company's annual dividend was 80 cents per share in fiscal 2000 but has since jumped to $1.08 per share. MS is currently yielding 1.7%. Moreover, the company repurchased approximately 22 million shares of its common stock since the end of fiscal 2005. Its return on equity of 22% is in line with the industry average.

Note: The Zacks Rank is a very sensitive indicator that can change frequently for an individual stock. This important indicator is updated daily on Zacks.com and is available to Zacks Premium subscribers. As such, it is prudent to check the site for the latest Zacks Rank on the stocks highlighted in this section. Simply click the link for the stock or enter the symbol in the ticker entry box in the upper left hand corner of the web site.

Content Courtesy: Zacks Investment Research

>>> Back to Table of Contents <<<

==============================================

6B) OMI Corporation (OMM)

==============================================

==============================================

7) About VitalStocks.com:

I believe America has incredible opportunities for people to succeed by making money in the stock market. After making and losing lots of money myself, I realized that there were no sources were investors could get unbiased valuable information.

That is what made me begin this project.  I continue to work with the top professional investing newsletters to bring “capsules” of their best stock picks to you.

Please help keep them participating in our newsletter, follow their links and see what services they provide.  Please consider sharing this with your friends. All will benefit.

Read More: http://www.vitalstocks.com/about_us.htm

 RSS Feed available: Fresh content each weekday http://feeds.feedburner.com/VitalstocksInvestingNewsletterDigest

==============================================